Careers  |  Sign In  |  Register  |   Twitter

Latest in Oncology

Reuters Health • The Doctor's Channel Daily Newscast

Dual HER2 Blockade Doesn’t Boost Cardiac Toxicity

By David Douglas NEW YORK (Reuters Health) - Dual HER2 blockade didn't increase heart problems in a meta-analysis of data from patients with HER2-positive breast cancer. "The combination of dual HER2 blockade is so far as safe as anti-HER2 monotherapy in terms of cardiotoxicity," Dr. Antonis Valachis...

Reuters Health • The Doctor's Channel Daily Newscast

Tailored Enteral Formula During Chemoradiotherapy Curbs Body Mass Loss

NEW YORK (Reuters Health) – For patients with head and neck or esophageal cancer undergoing chemoradiotherapy, enteral nutrition enriched with n-3 fatty acids helps preserve body mass. The finding comes from a randomized controlled trial conducted in Germany. It also indicated that such nutritional...

Reuters Health • The Doctor's Channel Daily Newscast

Hormonal Therapy May Be Reasonable in Stage IA Endometrial Cancer of All Grades

By Will Boggs, MD NEW YORK (Reuters Health) – Hormone therapy may suffice for women with stage IA endometrial cancer of all grades, if they want to try to become pregnant, a new study from Korea suggests. “The widely accepted indication for fertility-sparing progestin therapy for young women with...